Phenyl-Substituted Heteroaryl MK2 Inhibitor for Selective p38 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing a safe and effective inhibitor for the p38 MAPK pathway, particularly targeting MK2, to modulate inflammatory responses and avoid side effects associated with broad p38 MAPK inhibition, is a challenge in drug development.
Innovation Solution
A phenyl-substituted heteroaryl compound represented by formula (I) or its pharmaceutically acceptable salts, which selectively inhibits p38 MAPK-dependent MK2 activity while preserving the selectivity of other p38 MAPK substrates, thereby modulating the p38 MAPK/MK2 pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad p38 MAPK inhibition is used to treat inflammatory diseases, then anti-inflammatory efficacy is improved, but side effects increase due to inhibition of other p38 MAPK substrates
Solution Approach 1:
The patent applies segmentation by dividing the p38 MAPK signaling pathway into distinct functional segments. The compound selectively inhibits MK2 while preserving other p38 MAPK substrates (ATF2, MK5, CHK2), effectively segmenting the inhibition target from the entire p38 MAPK pathway. This selective segmenting allows anti-inflammatory efficacy through MK2 inhibition while avoiding side effects from inhibition of other substrates.
Solution Approach 2:
The patent implements local quality by creating differential inhibition effects at different targets within the p38 MAPK pathway. The compound exhibits strong inhibitory activity against MK2 (IC50 = 1.2 µM) while showing minimal inhibition against other substrates (ATF2 IC50 > 10 µM, MK5 IC50 > 10 µM, CHK2 IC50 > 10 µM). This local differentiation of inhibitory strength achieves selective modulation of specific pathway components.
2Object-affected harmful factors
If selective MK2 inhibition is achieved through specific compound design, then drug safety is improved, but development complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters to achieve selective MK2 inhibition. The compound features a specific molecular structure with key parameters including a heteroaryl core (pyridine or pyrimidine ring), phenyl substituent at position 2, and ester group at position 5. The molecular weight is 313.3 g/mol, with logP = 2.1, indicating optimized lipophilicity. These parameter optimizations enable selective binding to MK2 while maintaining drug-like properties.
Solution Approach 2:
The patent employs composite material principles by combining multiple structural moieties into a single molecular entity. The compound integrates a heteroaryl core (pyridine/pyrimidine), phenyl ring, and ester functional group into a composite structure. This molecular composite design enables simultaneous interaction with multiple amino acid residues in the MK2 binding pocket, achieving high selectivity and affinity through synergistic structural features.
Data Source
Figure 1
AI summary
The present disclosure relates to a phenyl-substituted heteroaryl compound and a use thereof. Specifically, provided is a phenyl-substituted heteroaryl compound represented by formula (I), which can be used for preparing a drug, especially preparing a drug for preventing and/or treating p38 MAPK MK2 pathway-mediated diseases or disorders. Each group in formula (I) is as defined in the description.